Clinical Report: Sjögren's Syndrome and the Role of B Cells

Background

Sjögren's syndrome is a systemic autoimmune disorder characterized by significant variability in clinical presentation, affecting multiple organ systems. The disease can lead to serious complications, including non-Hodgkin lymphoma. Understanding the role of B cells in the pathogenesis of SjD is crucial for developing targeted therapies.

Data Highlights

No numerical data provided in the source material.

Key Findings

• Sjögren's syndrome presents with a wide range of symptoms, from dryness to systemic manifestations.
• 30% to 50% of patients experience extraglandular manifestations.
• Endotyping may improve understanding and management of SjD by identifying pathobiologically similar subgroups.
• Current guidelines suggest B-cell targeted therapies like rituximab for severe, refractory cases.
• Research indicates sustained B-cell activation contributes to the disease's autoimmune processes.

Clinical Implications

Clinicians should be aware of the heterogeneous nature of SjD and consider endotyping for better management of the disease.

Conclusion

The understanding of Sjögren's syndrome continues to evolve, particularly regarding the role of B cells in its pathogenesis and treatment. Ongoing research is essential for improving patient outcomes.

Related Resources & Content

1. EULAR recommendations for the management of Sjögren’s syndrome with topical and systemic therapies, Annals of the Rheumatic Diseases, 2020 -- EULAR recommendations
2. Distinct Molecular Pathways Supporting Sjögren Disease Clusters and Disease Progression, Arthritis & Rheumatology, 2026 -- Molecular pathways in Sjögren's disease
3. Increased lymphoma risk in patients with systemic manifestations of Sjögren’s disease: a population-based study, Frontiers in Medicine, 2026 -- Lymphoma risk in Sjögren's
4. Pathogenesis of renal involvement in primary Sjögren’s disease: convergence of multifactorial mechanisms on immune dysregulation, Frontiers in Immunology, 2026 -- Renal involvement in Sjögren's
5. Frontiers in Immunology — Gut microbiota transfer from autoimmune dry eye mice imprints stereotypic B cell receptor repertoires in the lacrimal gland and induces disease
6. Mapping the B-cell axis in Sjögren’s disease: repertoire, microenvironment, and potential routes to precision treatment
7. Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren’s disease
8. EULAR recommendations for the management of Sjögren’s syndrome with topical and systemic therapies | Annals of the Rheumatic Diseases